Skip to main content
SpringerLink
Log in

Ifosfamide pharmacokinetics

  • Review Articles
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

This review examines and details the pharmacokinetics of ifosfamide (a congener of cyclophosphamide) when administered by a number of commonly used chemotherapeutic regimes. The influence of route of administration, schedule of administration and dose on the pharmacokinetics of ifosfamide and its metabolites are discussed. Oral fractionated ifosfamide therapy, which causes an excessively high incidence of neurotoxicity, is similar to intravenous fractionated therapy in that it exhibits a time dependent increase in ifosfamide metabolic clearance. Five g/m2 ifosfamide given intravenously as a short (half hour) or long (24 hr) infusion does not exhibit dose dependent (zero-order) pharmacokinetics. In patients who develop ifosfamide/mesna associated CNS toxicity the pharmacokinetics of parent ifosfamide are not aberrant. This implies that ifosfamide metabolites are more likely to be responsible for the neurotoxicity rather than the parent drug. The development of simple and more specific analytical methodology, will allow further studies of the pharmacokinetics of the active ifosfamide metabolite(s). This may lead to further optimisation of the therapeutic index of ifosfamide treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Coleman RE, Harper PG, Gallagher C, Osbourne R, Rankin EM, Silverstone AC, Slevin ML, Souhami RL, Tobias S, Trask GW, Wiltshaw E: A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix. Cancer Chemother Pharmacol 18:180–183, 1986

    Google Scholar 

  2. Brade WP, Herdrich K, Varini M: Ifosfamide — pharmacology, safety and therapeutic potential. Canc Treat Rev 12:1–47, 1985

    Google Scholar 

  3. Zalupski M, Baker LH: Ifosfamide. J Natl Cancer Inst 15, 80(8):556–566, 1988

    Google Scholar 

  4. Nelson RL, Allen LM, Creaven PJ: Pharmacokinetics of divided dose ifosfamide. Clin Pharmacol Ther 19(3):365–370, 1976

    Google Scholar 

  5. Piazzo E, Cattaneo MT, Varini M: Pharmacokinetic studies on lung cancer patients. Cancer 54(6), Supp:1187–1192, 1984

    Google Scholar 

  6. Thatcher N, Anderson H, Smith DB, Steward WP, Webb K, Rahman A: Ifosfamide by bolus treatment for advanced Non Small Cell Lung Cancer. Cancer Chemother Pharmacol 18(Supp. 20):S30-S33, 1986

    Google Scholar 

  7. Pearcey R, Calvert R, Mehta A: Disposition of ifosfamide in patients receiving ifosfamide infusion therapy or the treatment of cervical carcinoma. Cancer Chemother Pharmacol 22(4):353–355, 1988

    Google Scholar 

  8. Scheef W, Klein HO, Brock N, Burkert H, Gunther U, Hoefer-Janker HJ, Mitrenga D, Schnitker J, Voigtman R: Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results. Canc Treat Rep 63(3):501–505, 1979

    Google Scholar 

  9. Scheulen ME, Niederle W, Bremer K, Schutte J, Seber S: Efficacy of ifosfamide in refractory malignant diseases and uroprotection of mesna, results of a clinical phase II study with 157 patients. Canc Treat Rev 10(Supp. A):93–101, 1983

    Google Scholar 

  10. Schaumloffel E: Pharmacokinetics of ifosfamide in animals and man: Proc. of the Int. Holoxan Symposium, Düsseldorf, Asta Werke, W.G. p. 13–15, 1977

  11. Cerny T, Margison J, Thatcher N, Wilkinson PM: Bioavailability of oral ifosfamide in patients with bronchial carcinoma. Cancer Chemother Pharmacol 18:261–264, 1986

    Google Scholar 

  12. Wagner T, Drings P: Pharmacokinetics and bioavailability of oral ifosfamide. Arzneim Forsch (Drug Res) 36(I)5:878–880, 1986

    Google Scholar 

  13. McNeil NO, Morgan LR: The bioavailability of oral and intravenous ifosfamide in the treatment of bronchogenic carcinoma. Int J Clin Pharmacol, Therapy and Toxicology, 19:490–493, 1981

    Google Scholar 

  14. Bagley CM, Bostick FW, De Vita VT: Clinical Pharmacology of cyclophosphamide. Cancer Res 33:226–233, 1973

    Google Scholar 

  15. D'Incalci M, Bolis G, Facchinetti TT, Mangioni C, Morascu L, Morrazoni P, Salmona M: Decreased half life of cyclophosphamide in patients under continual treatment: Eur J Cancer 15:7–10, 1979

    Google Scholar 

  16. Schuler U, Ehninger G, Wagner T: Repeated high dose cyclophosphamide administration in bone marrow transplantation; exposure to active metabolites. Cancer Chemother Pharmacol 3:248–252, 1987

    Google Scholar 

  17. Lind MJ, Margison JM, Cerny T, Thatcher N, Wilkinson PM: Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with lung cancer. Cancer Res 49:753–757, 1989

    Google Scholar 

  18. Lind MJ, Roberts HL, Thatcher N, Idle JR: The effect of route of administration and fractionation on the metabolism of ifosfamide: Cancer Chemother Pharmacol 26:105–111, 1990

    Google Scholar 

  19. Juma FD, Rogers HJ, Trounce JR: Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration. Br J Clin Pharmac 8(3):209–217, 1979

    Google Scholar 

  20. Lewis LD, Fitzgerald D, Harper PG, Rogers HJ: Fractionated ifosfamide therapy produces a time dependent increase in ifosfamide metabolism. Br J Clin Pharmac 30(5):725–732, 1990

    Google Scholar 

  21. Sladek NE: Metabolism of oxazaphosphorines. Pharmac Ther 37(3):301–355, 1988

    Google Scholar 

  22. Graham MI, Shaw IC, Souhami RL, Sidau B, Harper PG, MacLean AE: Decreased plasma half-life of cyclophosphamide during repeated high dose administation. Cancer Chemother Pharmacol 10:192–193, 1983

    Google Scholar 

  23. Allen LM, Creaven PJ: In vitro activation of isophosphamide a new oxazaphosphorine by rat liver microsomes. Cancer Chemother Rep 56(I,5):603–610, 1972

    Google Scholar 

  24. Allen LM, Creaven PJ: Activation of the antineoplastic drug isophosphamide by rat liver microsomes. J Pharm Pharmacol 24:585–586, 1972

    Google Scholar 

  25. Connors TA, Cox PJ, Farmer PB, Jarmen M: Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and ifosfamide. Biochem Pharmacol 23:115–129, 1974

    Google Scholar 

  26. Brock N: Oxaphosphorine cytostatics: Structure-activity relationships, selectivity and metabolism, regional detoxification. In Reinhoudt DN, Connors TA, Pinedo HM, et al. (eds): Structure Activity Relationships of Anti-Tumour Agents. The Hague, The Netherlands, Martinus Nijhoff p. 239–267, 1983

    Google Scholar 

  27. Sarosy G: Ifosfamide — Pharmacologic Overview. Sem Oncol 16(1), Supp. 3:2–8, 1989

    Google Scholar 

  28. Wagner T: Alkylating activity in serum, urine and CSF following high dose ifosfamide in children — a comment. Cancer Chemother Pharmacol 24:S7, 1989

    Google Scholar 

  29. Allen LM, Creaven PJ, Nelson R: Studies on the human pharmacokinetics of isophosphamide (NSC.109724). Cancer Treat Rep 60(4):451–458, 1976

    Google Scholar 

  30. Creaven PJ, Allen LM, Alford D, Cohen M: Clinical pharmacology of isophosphamide. Clin Pharmacol Ther 16:77–86, 1974

    Google Scholar 

  31. Creaven PJ, Allen LM, Cohen MH, Nelson RL: Studies on the clinical pharmacology and toxicology of isophosphamide (NSC.109724). Cancer Treat Rep 60(4):445–449, 1976

    Google Scholar 

  32. Lewis LD, Fitzgerald D, Mohan P, Thatcher N, Harper PG, Rogers HJ: The pharmacokinetics of ifosfamide when given as short or long infusions in cancer patients. Br J Clin Pharmac 31(1):77–82, 1991

    Google Scholar 

  33. Ninane J, Baurain R, de Kraker J, Ferster A, Trouet A, Cornu G: Alkylating activity in serum, urine and CSF following high dose ifosfamide in children. Cancer Chemother Pharmacol 24(Supp.):S2-S6, 1989

    Google Scholar 

  34. Gibson GG, Tamburini PP: Cytochrome P-450 spin state: inorganic biochemistry and functional significance. Xenobiotica 14:27–47, 1984

    Google Scholar 

  35. Philip PA, Lewis LD, James CA, Rogers HJ: Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation. Cancer Chemother Pharmacol 22(4):321–324, 1988

    Google Scholar 

  36. Mouridsen HT, Faber G, Skovsted L: The metabolism of cyclophosphamide. Dose dependency and effect of long term treatment with cyclophosphamide. Cancer 37:665–670, 1976

    Google Scholar 

  37. Wilkinson PM, O'Neill PA, Thatcher N, Lucas SB: Pharmacokinetics of high dose cyclophosphamide in patients with metastatic bronchogenic carcinoma. Cancer Chemother Pharmacol 11:196–199, 1983

    Google Scholar 

  38. Lind MJ, Margison JM, Cerny T, Thatcher N, Wilkinson PM: The effect of age on the pharmacokinetics of ifosfamide: Br J Clin Pharmacol 30:140–143, 1990

    Google Scholar 

  39. Lind MJ, Margison JM, Cerny T, Thatcher N, Wilkinson M: Prolongation of ifosfamide elimination half life in obese patients due to altered drug distribution. Cancer Chemother Pharmacol 25(2):139–142, 1989

    Google Scholar 

  40. Powis G, Reece P, Ahmann DL, Ingle JN: Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother Pharmacol 20:219–222, 1987

    Google Scholar 

  41. Meanwell CA, Blake AE, Kelly KA, Honigsberger L, Blackledge G: Prediction of ifosfamide/mesna associated encephalopathy. Eur J Canc Clin Onc 22:815–819, 1986

    Google Scholar 

  42. Lewis LD, Meanwell CA: Ifosfamide pharmacokinetics and neurotoxicity. Lancet 335:175–176, 1990

    Google Scholar 

  43. Goren MP, Wright RK, Pratt CB, Pell FE: Dechloroethylation of ifosfamide and neurotoxicity. Lancet ii:1219–1220, 1986

    Google Scholar 

  44. Norpoth K: Studies on the metabolism of isophosphamide (NSC-109724) in man. Canc Treat Rep 60:437–443, 1976

    Google Scholar 

  45. Lind MJ, McGown AT, Hadfield JA, Thatcher N, Crowther D, Fox BW: The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo. Biochem Pharmacol 38(11):1835–1840, 1989

    Google Scholar 

  46. Cerny T, Kupfer A: Stabilisation and quantitative determination of the neurotoxic metabolite chloroacetaldehyde in the plasma of ifosfamide treated patients. Abstract. Proceedings of ECCO-5. London. P0147, 1989

  47. Klein OH, Wickramanyake PD, Christian E, Coerper C: Therapeutic effects of single push or fractionated injections or continous infusion of oxazaphosphorine (Cyclophosphamide, Ifosfamide, Asta Z 7557). Cancer 54(Supp. 6): 1193–1201, 1984

    Google Scholar 

  48. Morgan LR, Harrison EF, Hawke JE, Hunter HL, Costanzi JJ, Plotkin D, Tucker WG, Worrell PM: Toxicity of single vs. fractionated dose ifosfamide in Non Small Cell Lung Cancer: A multicentre study. Sem Oncol 9(Supp. 1):66–67, 1982

    Google Scholar 

  49. Radford JA, Margison JM, Swindell R, Lind MJ, Wilkinson PM, Thatcher N: The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump. Cancer Chemother Pharmacol 26:144–146, 1990

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Clinical Pharmacology, The Johns Hopkins Hospital, Baltimore, Maryland, USA

    L. D. Lewis (Postdoctoral Fellow)

Authors
  1. L. D. Lewis
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lewis, L.D. Ifosfamide pharmacokinetics. Invest New Drugs 9, 305–311 (1991). https://doi.org/10.1007/BF00183570

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00183570

key words

Search

Navigation